Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Peptides for Postpartum Recovery — Clinical Comparison

Collagen Peptides Fibroblast stimulation via dipeptide signaling; increases procollagen type I expression Strong (8+ RCTs, 1,000+ participants) 10–15g oral daily Skin markers improve at 4–8 weeks; joint effects at 12–24 weeks Best-supported option for connecti

This comparison does not assign a generated winner or score.

  • Collagen Peptides
  • Fibroblast stimulation via dipeptide signaling; increases procollagen type I expression
  • Strong (8+ RCTs, 1,000+ participants)
  • 10–15g oral daily
  • Skin markers improve at 4–8 weeks; joint effects at 12–24 weeks
  • Best-supported option for connective tissue repair; safe during lactation; bioavailable oral delivery
  • BPC-157
  • VEGF upregulation; accelerates angiogenesis and epithelial migration
  • Moderate (animal models only; no human RCTs)
  • 200–500mcg/kg subcutaneous in animal studies
  • Wound healing effects within 7–14 days in rodent models
  • Promising preclinical data but zero human postpartum trials; legal status varies by region
  • Thymosin Beta-4 (TB-4)
  • Actin sequestration; promotes cell migration and angiogenesis
  • Moderate (Phase I/II human safety data; no postpartum trials)
  • 5–10mg subcutaneous weekly in cardiac trials
  • Cardiac function improvement at 4 weeks in MI patients
  • Mechanistically plausible for tissue repair; human data exists but not in postpartum population
  • Thymalin
  • T-cell maturation; shifts Th2-dominant state toward balanced Th1/Th2
  • Weak (small trials in autoimmune populations; no postpartum-specific research)
  • 5–10mg intramuscular 2–3x weekly
  • Immune markers normalize over 4–8 weeks in limited trials
  • Theoretical benefit for immune recalibration; minimal human data; not commercially available in most regions
  • GHK-Cu (Copper Peptide)
  • Stimulates collagen and glycosaminoglycan synthesis; modulates metalloproteinase activity
  • Moderate (dermatology trials; no postpartum-specific research)
  • 1–3% topical or 1–2mg subcutaneous
  • Skin remodeling visible at 4–12 weeks
  • Established in wound healing and skin rejuvenation; oral bioavailability poor; topical or injectable only
More references

Related material